Background: Neuroinflammation has gained substantial attention for its involvement in the progression of Alzheimer's disease (AD).
Method: Recently, it was discovered that platelets, which make up 90% of the circulatory Aβ, encourage the development of AD. Therefore, we hypothesized to use a novel coumarin derivative PS21HKR, which is believed to possess anti-platelet and anti-inflammatory properties for the treatment of AD. We investigated the effects of PS21HKR on STZ induced cognitive decline and neuroinflammation. Intra-cerebroventricular streptozotocin (ICV-STZ) (3mg/Kg) induced Wistar rat models of AD were used in the study. Rats were divided into 3 groups including sham, STZ and PS21HKR group.
Result: Behavioural studies revealed that PS21HKR mitigates the cognitive deficit associated with STZ. Anti-platelet effect of PS21HKR was confirmed by tail vein bleeding assay. Further, in-vitro studies were performed on BV2 cells including the MTT assay and determination of expression of inflammatory markers. The results suggested that PS21HKR potentially regulated the expression of pro- and anti-inflammatory cytokines.
Conclusion: Therefore, findings of this study indicate that PS21HKR has a potent neuroprotective effect by virtue of its anti-platelet and anti-inflammatory activity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/alz.090252 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Central University of Punjab, Bathinda, Punjab, India.
Background: Neuroinflammation has gained substantial attention for its involvement in the progression of Alzheimer's disease (AD).
Method: Recently, it was discovered that platelets, which make up 90% of the circulatory Aβ, encourage the development of AD. Therefore, we hypothesized to use a novel coumarin derivative PS21HKR, which is believed to possess anti-platelet and anti-inflammatory properties for the treatment of AD.
Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke Stratified by Risk Profile: A Post Hoc Analysis.
Stroke
January 2025
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China (Y.Z., X.W., Y.G., W.C., H.Y., T.W., Y.Y., Q.Z., M.W., J.J., C.W., Yongjun Wang, Yilong Wang, Y.P.).
Background: Risk profile of recurrence may influence the effect of antiplatelet therapy. This study aimed to evaluate the efficacy and safety of clopidogrel-aspirin initiated within 72 hours after symptom onset for acute mild stroke or high-risk transient ischemic attack stratified by risk profile.
Methods: This is a secondary post hoc analysis of the INSPIRES (Intensive Statin and Antiplatelet Therapy for Acute High-risk Intracranial or Extracranial Atherosclerosis) randomized clinical trial that enrolled patients 35 to 80 years old with acute mild ischemic stroke or high-risk transient ischemic attack between 2018 and 2022.
Postoperative bleeding in myocardial revascularization under cardiopulmonary bypass for patients treated with aspirin or dual antiplatelet therapy using reduced goal-directed anticoagulation.
Eur J Cardiothorac Surg
December 2024
Cardiac Surgery Department, University Hospital of Angers, 4 Rue Larrey, Angers, 49100, France.
Objectives: Antiplatelet therapy increases the risk of bleeding and transfusion in patients undergoing extracorporeal circulation. Reduced goal-directed anticoagulation is a personalized approach to reduce the anticoagulation based on a lower targeted activated clotting time. We assessed whether reduced goal-directed anticoagulation using optimized extracorporeal circulation alleviates the risk of severe bleeding in patients treated by dual antiplatelet therapy (DAPT) compared to aspirin alone during coronary artery bypass grafting (CABG).
View Article and Find Full Text PDFThe chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study.
BMC Med
December 2024
Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Article Synopsis
- Non-alcoholic fatty liver disease (NAFLD) is linked to higher rates of liver and obesity-related cancers, prompting researchers to investigate the protective effects of aspirin and other anti-platelet drugs on these cancers.
- A study analyzed medical records of adults with NAFLD to compare the cancer incidence between those taking antiplatelet medication for at least a year versus those who weren't, following them for five years.
- Results indicated that antiplatelet use significantly lowered the risk of obesity-related cancers, including hepatocellular carcinoma (HCC), breast, pancreatic, and colorectal cancers, with aspirin alone showing a major decrease in HCC incidence.
Fixed-Dose Antiplatelet Dual Combination in Patients with Coronary Artery Disease in Turkish Population: DAPT-TR.
Arq Bras Cardiol
October 2024
Ege University, Department of Cardiology, Izmir - Turquia.
Article Synopsis
- Dual antiplatelet therapy (DAPT) is essential for managing acute and chronic coronary syndromes, helping to lower mortality rates and prevent further complications.
- A study followed 1500 patients on a specific fixed-dose DAPT (ASA + clopidogrel) to evaluate its effectiveness and safety, primarily focusing on hospitalization and bleeding risks.
- Results indicated that the fixed-dose combination therapy was effective, with low rates of hospitalization for cardiovascular issues and minimal bleeding complications in appropriately selected patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!